EUVIMEDEUVIMED entdecken
Crossref

International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis

Joseph F Merola, Beth A Childs, Brooke R Bartley, Robert Bissonnette, Thomas Bieber, Emma Guttman-Yassky, Amy S Paller, Eric L Simpson, April W Armstrong, Alan D Irvine

JAMA Dermatology · 01.06.2026 · 162 (6) · 631

DOI: 10.1001/jamadermatol.2026.0662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2026. Verfasst von Joseph F Merola und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O'Donnell School of Public Health,…. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Advances in targeted therapeutics have made substantial response states in atopic dermatitis (AD) increasingly attainable. However, the field lacks standardized, internationally endorsed definitions of low disease activity (LDA), very low disease activity (vLDA), and remission to benchmark treatment response, support regulatory clarity, and enable consistent cross-trial comparisons.

Objective

To develop consensus-based definitions of LDA, vLDA, and remission in AD that accommodate regional regulatory frameworks and to refine associated terminology for clinical and research use. Evidence Review A steering committee from the International Eczema Council (IEC) conducted a targeted systematic literature review. PubMed was searched in July 2024 for studies from January 1, 2004, through December 31, 2024, using combinations of terms related to atopic dermatitis, clinician-reported outcomes, patient-reported outcomes, disease control states, pruritus measures, and disease activity constructs. Evidence was appraised using the Oxford Centre for Evidence-Based Medicine criteria. Key conceptual domains were identified to inform a 3-round sequential modified Delphi process conducted from January to July 2025. Panelists (current IEC members with recognized AD expertise) iteratively reviewed feedback, refined thresholds, and provided qualitative rationale. Predefined criteria distinguished consensus (≥70% agreement), near consensus (60%-69%), and nonconsensus (<60%), guiding which cutoffs were adopted, revised, or excluded.

Findings

Of the 151 experts invited, 61 (40%) completed round 1, 37 (25%) completed round 2, and 103 (68%) completed round 3. Responses from participants were globally distributed (North America: 59 [29%]; Europe: 47 [23%]; Asia-Pacific: 60 [30%]; Latin America 27 [13%]; Middle East and Africa: 7 [3%]), including 131 clinician-researchers (66%), 59 clinicians (30%), and 9 researchers (5%); 17 respondents (8%) self-identified as individuals with lived AD experience and/or patient advocacy representatives. A total of 43 panelists (74%) endorsed a modular framework that stratifies clinician-reported signs and patient-reported symptoms as complementary components of remission (eg, remission [signs], remission [symptoms], remission [overall]) in the initial survey. Final consensus definitions included LDA (validated Investigator Global Assessment for Atopic Dermatitis [vIGA] = 2 or Eczema Area and Severity Index [EASI] ≤ 7 plus Peak Pruritus Numerical Rating Scale [PP-NRS] ≤ 4), vLDA (vIGA-AD = 0/1 or EASI ≤ 3 plus PP-NRS = 0/1), on-drug complete control (ie, complete control while taking AD-related medications, excluding only nonmedicated moisturizers/emollients, defined as vIGA-AD = 0 or EASI = 0 plus PP-NRS = 0/1 for ≥6 months), and off-drug remission (ie, remission after stopping treatment, defined as vIGA-AD = 0 or EASI = 0 for plus PP-NRS = 0/1 maintained for ≥12 months after treatment). Conclusions and Relevance This modified Delphi initiative establishes a globally endorsed, expert-derived framework defining LDA, vLDA, on-drug complete control, and off-drug remission in AD. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. By promoting consistent assessment of disease control across studies, this framework advances the field toward evidence-based, treat-to-target AD strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansDelphi TechniquePatient Reported Outcome MeasuresPruritusRemission InductionSeverity of Illness Index

Autor:innen und Institutionen

  • Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, Texas.
  • Innovaderm Research, Montreal, Quebec, Canada.
  • The Christine Kühne Center for Allergy Research and Education, Medicine Campus, Davos, Switzerland.
  • Bieber Dermatology Consulting, Feldafing, Germany.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Zitieren

APA

Merola, J. F., Childs, B. A., Bartley, B. R., Bissonnette, R., Bieber, T., Guttman-Yassky, E., Paller, A. S., Simpson, E. L., Armstrong, A. W., & Irvine, A. D. (2026). International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis. JAMA Dermatology, 162(6), 631. https://doi.org/10.1001/jamadermatol.2026.0662

Vancouver

Merola JF, Childs BA, Bartley BR, Bissonnette R, Bieber T, Guttman-Yassky E, et al. International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis. JAMA Dermatology. 2026;162(6):631. doi:10.1001/jamadermatol.2026.0662

BibTeX
@article{Merola2026,
  author = {Merola, Joseph F and Childs, Beth A and Bartley, Brooke R and Bissonnette, Robert and Bieber, Thomas and Guttman-Yassky, Emma and Paller, Amy S and Simpson, Eric L and Armstrong, April W and Irvine, Alan D},
  title = {International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis},
  journal = {JAMA Dermatology},
  year = {2026},
  volume = {162},
  number = {6},
  pages = {631},
  doi = {10.1001/jamadermatol.2026.0662}
}
Kostenlos starten →